Pharmacology
All Targets
7-TM Receptors
Ion Channels
Nuclear Receptors
Enzyme-Linked Receptors
Transporters
Enzymes
Other Pharmacology
Cellular Processes
Angiogenesis
Apoptosis
Cell Cycle
Cell Metabolism
Cytoskeleton & Motor Proteins
ECM & Adhesion Molecules
Epigenetics 
Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
Monoamine Oxidase
More Information »Monoamine Oxidases (MAO) catalyze the oxidation of monoamines such as dopamine, serotonin and adrenalin. They are found bound to the outer membrane of mitochondria in most cell types in the body. Two subtypes of MAO have been identified: MAO-A and MAO-B.
Monoamine Oxidase Products
Inhibitors |
|
Cat.No. |
Product Name / Activity |
| 3306 | 8-(3-Chlorostyryl)caffeine |
| MAO-B inhibitor. Also A2A inhibitor | |
| 0767 | Bifemelane hydrochloride |
| MAO-A and MAO-B inhibitor | |
| 1095 | (R)-(-)-Deprenyl hydrochloride |
| MAO-B inhibitor | |
| 1132 | Harmane |
| MAO-A and MAO-B inhibitor | |
| 2460 | Lazabemide hydrochloride |
| Selective MAO-B inhibitor | |
| 4395 | Moclobemide |
| Reversible MAO-A inhibitor | |
| 0724 | Pirlindole mesylate |
| MAO-A inhibitor | |
| 4308 | Rasagiline mesylate |
| Selective, irreversible MAO-B inhibitor | |
| 0723 | Tetrindole mesylate |
| MAO-A inhibitor | |
| 3852 | Tranylcypromine hydrochloride |
| Irreversible inhibitor of MAO-A, MAO-B and LSD1 | |
Related Categories
Quick Order
Find multiple products by catalog number
Neurobiology of Parkinson's Disease
Written by A. Schapira
'Neurobiology and Therapeutics of Parkinson's Disease' highlights the neurobiology of Parkinson's disease and summarizes current and novel therapeutic interventions.
Antidepressants - Current and Future Targets
Written by P. Skolnich et al
'Antidepressants - Current and Future Targets' provides an overview of the current and future targets for the treatment of major depressive disorder.
20% Discount*
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.